Juvenile-HD

HOME

INDEX Page
Tools For Viewing
10 The Most Commonly Asked Questions
Clinical Trials & Research
Huntington's Disease~WeMove Info
Advocacy/Donations/Press Info
Clinical Definition & Search
Facing HD~Family Handbook
JHD Handbook-Chapter 1
JHD Info-Stanford Univ.
Physician's Guide To HD
Caring for People with HD
Physical & Occupational Therapy In HD
Understanding Behaviour in HD-Dr. Jane Paulsen
Understanding Behavioral-Dr. Edmond Chiu
Advanced Stages Caregivers Handbook
First Shift-Certified Nursing Assistants
Activities of Daily Living-HD
Unified HD Rating Scale (UHDRS) Motor Section
Westphal Variant
SECTION 1 - AT RISK
Age & Probability Chart
At Risk For HD-What Next?
At-Risk Checklist
Best Interest of Child?
Crystal Ball?
Food For Thought
Parent Hasn't Tested?
Q&A On Risk of Inheriting JHD
Testing Children
SECTION 2 - GENETIC TESTING
Genetic Disorders & Birth Defects
Genetic Testing for HD
Genetic Counseling-In General
Psychological Impact
Intro: Genetics/Genetic Testing
Prenatal & Preimplanation
Prenatal Testing-In General
o Genetic Testing Resources
o Personal Stories
SECTION 3 - JHD
Coping With The Early Years
Age of HD Appearance
Age of Onset-Historical
Family-HD Underestimated
Children of Parents With HD
Child~Parent Ill
Clinical Description JHD
HD - What Kids Are Saying
HD & Me
JHD-Duration of Illness
JHD-Clinical and Research
JHD Symptoms
Parenting With HD
Patients/Families Coping
Talking With Children About HD
5 Stages of HD
JHD Resources
SECTION 4 - SYMPTOM RECOGNITION
Parent Resources
8 Fears of A Chronic Illness
Anxiety/Apathy/Irritability~HD
Anxiety, Fears & Phobias
Apathy-Physician's Guide
Ataxia
Attention-Perceptual/Unawareness Physician's Guide
Bed/Pressure Sores
Bed/Pressure Ulcer Guideline
Behavior Management
Bi-Polar Disorders
Botulinum toxin therapy
Bradykinesia
Caring Tips
Child Abuse-Reconizing Signs
Chorea-Physician's Guide
Chorea
Cognitive/Decision Making/Impulsivity
Cognitive-Short Tips
Contractures~Joints Locking
Dehydration-Physician's Guide
Dehydration
Delirium
Denial of HD
Depression~Physician's Guide
Depression-Understanding It
Depression-How To Help
Depression - Treatment Resistant Patient
Depression-Other Resources
-Read If Your Child Is On Antidepressant
Disgust - Impaired Recognition in HD
Dissociative disorders
Driving - Physician's Guide
Dyslexia
Dyslexia Resources
Dystonia
Dystonia/Rigidity & Spasticity Physician's Guide
Dystonia-Predominant Adult-Onset HD
Epileptic Seizures and Epilepsy
Epilepsy-Seizures~PG
-Seizures ~Special Populations
Falling~Safety
Falling - Subdural Hematoma Risk
Fevers - Unexplained
Fevers, sweating & menstural cycles in HD
GERD (Stomach)
HD Principle Treatments
Hallucinations/Psychosis~PGHD
Hand muscle reflexes in HD
Hypothalamus - A Personal Theory
Insomia ~Physician's Guide
Irritability~Temper Outburst Physician's Guide
Learning Disability
Mania/OCD~Physician's Guide
Mood Disorder Rate In HD
Myoclonus (Movements)
Nails-What To Look For
Night Terrors
Obsessive Compulsive OCD
Panic Disorder
Personality disorders
Pneumonia
Pneumonia-Advanced Stages
Pneumonia - Aspirated (Inhaled)
Prosody - Social Impairment
Sexuality~Physician's Guide
Skins Sensitivity
Sleep Disorders
Smoking-Physician's Guide
Spasticity
Stress
Tremors
Why Certain Symptoms Occur
Symptom & Treatment Resources
SECTION 5 - COMMUNICATION
Communication Resources
Communication Problems
Communication Strategies For HD~Jeff Searle
SECTION 6 - EATING/SWALLOWING/NUITRITION
Hints For Weight Loss in HD
HD & Diet~HSA Fact Sheet 7
Nutrients: Some Possible Deficiency Symptoms
Nutrition and HD~Anna Gaba (Recipes)
Nutrition Information In HD~Naomi Lundeen
Speech & Swallowing~Lynn Rhodes
Swallowing & Nutrition Physician's Guide To HD
Swallowing & Nuitrition Resources
Swallowing Warning Signs
5 Swallowing Problems
Taste changes in HD
Weight Gain
Resources-Drinks/Shakes
-Feeding Tubes~Advanced Stages of HD
-Feeding Tube~Jean Miller
-Feeding Tubes: One More Word ~Jean Miller
-Feeding Tubes & Baby Foods
-Feeding Tube~Dental Care
-Feeding Tube Instructions~Jean Miller
-Feeding Tube Resources
SECTION 7 - THERAPIES
Finding a Therapist - Behavoir
What Is A Physiotherapist?
Physical Therapy In HD
Speech-Language Therapy
Therapy Descriptions
Therapy Resources- Easter Seal
Therapy Resources
SECTION 8 - MEDICATIONS
HD Treatments
Medications-Movement Disorders
Medication/Emergency Info Forms
Cutting Prescriptions
Drugs-Look 'Em Up
-Adolescents Under 25
-Antidepressant Adverse Effects
-Anti-psychotic
-Anxiety-Antidepressant
A-Z Mental Health Drugs
-Creatine
-EPA~Fish Oil
-Haldol/Haloperidol - Clinical Sheet
-Haldol~Clinician Description
-Haldol & HD
-Haldol/HD Patient Experiences
-Haldol~ Patient Handout
-Mood Stabilizers: ASK 3 Questions
-Neuroleptic Malignant Synd WARNING
-Olanzipine-Risperidone/blood tests
-Celexa/Luvox/Paxil/Prozac/Zoloft
-Psychiatric Drugs & Children
Sertraline ~Zoloft
-Spasticity Meds/Treatments
-SSRI Medications
-Tardive Dyskinesia WARNING
-Weight Gain Medications
-Sites/Help the Medicine Go Down
-Vitamin & Mineral Deficiencies
SECTION 9 - SURGERIES
Surgery-Movement Disorders
o Surgery Resources
SECTION 10 - PROCEDURES
Clinic Visits-How To Prepare
CT Scans, MRI's etc.
Swallowing Tests
Tests Commonly Used
o Procedures Resources
SECTION 11- ALCOHOL/DRUGS
Alcohol-Parent's Guide
Alcohol-Talking To Your Child
Drugs-What To Do?
Drugs-Talking To Your Child
Disciplining-Ages 0-13 & Up
SECTION 12- SUICIDE
Straight Talk On Suicide
Teen Suicide-You Need To Know
o Suicide Resources
SECTION 13 - DIVORCE
Divorce & Child Stress
Tips For Divorcing Parents
SECTION 14 - DISABILITY ISSUES
Guides To Disability Issues
Caring-Child & Medical Technology
Caring for a Seriously Ill Child
Child Long Term Illness
Disability-Special Education Plan
IFSP Early Intervention Process
Disability Resources
Financial Planning
Wishes Can Come True-Children's Wish Foundations
Special Needs Resources
Special Needs Camp - About
Special Needs Camp - Finding One
SECTION 15 - ASSISTIVE TECHNOLOGY
Child Assistive Technology
Adaptive Equipment Resources
Products
SECTION 16 - EMOTIONAL ISSUES
Signs of Unhealthy Self-Esteem
Emotional Behavior Links
o Emotional Support Resources
SECTION 17 - GRIEF
Helping Child Deal With Death
o Grief Addtional Resources
SECTION 18 - ADD/ADHD
ADD & Teens
Conduct Disorders
FAQS & Related Info
Understanding AD/HD
What Is AD/HD?
Research Articles
Resources
SECTION 19 - HD SUPPORT GROUPS
HD Support Groups
National Youth Association
SECTION 20 - HD LINKS
HD Links
Related Resources
Tips For Friends
SECTION 21 - BENEFITS/INSURNACE
HD Disability
Benefits Check UP - See What You Can Get
Medical Insurance Bureau's Facts On You!
Medicare-Medicaid
Medicare Rights-Home Health & Hospice
Medicare Rights Center Resources
No Insurance? Try This!
Prescription Drug Cards Part I
Prescription Drug Cards Part II
Social Security-Children With Disabilities
SECTION 22 - ARTICLES/JHD
JHD and ADD
SECTION 23 - CAREGIVING
Articles-Resources
Caregiver Self-Assessment
Caregiver's Handbook
"First Shift With A Person With HD"
Getting Respite Care/Help At Home
Helpful Forms-Info
Home Emergency Preparations
Symptom Management
Ten Tips
Useful Tools
SECTION 24 - BIO
Our Personal Experience
Coping At The End
Kelly E. Miller
Song & Verse
Letter From My Heart
GUESTBOOK
-Mood Stabilizers: ASK 3 Questions

INDEX Page

"Medscape Psychopharmacology Today" is a monthly column on issues and topics that are new and important in psychiatry and psychopharmacology. Geared to the practicing clinician, it will provide information about upcoming issues and advances in the field.

What dose of a particular medication should be used for a particular patient?

Dosing questions are probably the most common and most difficult questions that clinicians grapple with. We assume that there is some way to determine the appropriate dose before initiation of treatment; however, usually the only definitive answer is, "Whatever ends up working the best."

The primary issues related to dosing are (1) individual variation and (2) the discrepancy between the best dose for minimizing side effects and the best dose for treatment response. Drug companies tend to focus on the former at the expense of the latter.
 
Individual variation includes not only differences among people in terms of such issues as absorption and metabolism but also variations among the disorders themselves.

For example, does everyone we diagnose with major depression have the same disorder? Probably not.

Everybody is different. Everyone with ostensibly the same disorder does not respond to the same medication or at the same dose. It is intriguing to speculate why, but no one really knows. It is particularly interesting to note that studies have shown no correlation between plasma level and treatment response for selective serotonin reuptake inhibitors (SSRIs). Perhaps that suggests that it does not matter very much what dose is administered to a patient.

Most of the time we give medicines by mouth, and this can account for a great deal of variation, due in large part to big differences in our diets. People who live mostly on salads probably absorb medicine differently than people who live mostly on cheeseburgers.

We also vary a great deal as to how fast we metabolize medicine. Studies have shown that there is enormous variation between individuals, even those with the same ethnic background, in terms of the potency of the various cytochrome P450 enzymes. These enzymes that are responsible for much of drug metabolism may vary from person to person by as much as 30%. For example, the blood level of quetiapine, at the same dose may vary as much as 40 times between patients.

Add in the other medications the patient is taking that may or may not interfere with or induce metabolism, and it becomes extremely hard to predict an optimal dose. It is important to remember  that almost all drug interactions are reported retrospectively; despite all we know about drug metabolism, specific and sometimes significant interactions are very hard to predict.

Usually, the smaller the dose of a medication, the fewer side effects, although there are exceptions: Venlafaxine seems to be tolerated better at higher rather than lower doses.

When pharmaceutical companies come out with a new drug, they often try to market it at a very low dose to minimize side effects. As a result, clinicians can be unimpressed with the drug until they try it at doses higher than the initial recommended dose.

Examples of this are olanzapine, nefazodone, and quetiapine. Risperidone was marketed at too high a dose for the same reason: the clinical trials were designed to find the highest dose at which side effects were minimal, not the highest treatment response. As a result, the drug was originally marketed at 6 mg/day. Now we know that for most patients the drug works better, particularly for negative symptoms of schizophrenia, in the 2- to 4-mg/day range.

What is the relationship between dose and response? For the most part, it varies depending on the drug. As discussed above, for risperidone, a lower dose often produces a better response.

For SSRIs, it gets flat - so that increasing the medication dose usually does not improve the patient and after a while, there is no point increasing the dose if the patient isn't getting better.

For valproate, the more medicine administered (and the higher the plasma levels), the more likely the patient will get better, but also the more likely there will be side effects.

Another problem that is important to keep in mind is that there is no clear definition of treatment response. We are generally clear about when a patient is better, but less clear on when they are able to resume premorbid functioning levels and how long that should take. The scientific literature is, at best, confusing on the subject.

Most studies are 6 weeks long. Is that long enough? How long does it take to get better? How much influence does dose have on that? Do higher doses mean faster recovery? Although we have no definitive answers to any of these questions, as
clinicians we often behave as if we believe that more drug means better or faster.

If a patient is, for example, somewhat better but not significantly better in 2 weeks, we will often increase the dose. If in 4 weeks they are significantly improved, was it the increased dose, or would 2 more weeks on the original dose also have made them better?

We tend to think of the dosing of a medication as a well-established procedure. It is not. In fact, many patients may have "failed" medications that they would have responded to if they were given more time or a different dosage. The only way to dose a new medication is to make an educated guess and adjust from there. There is no perfect starting dose or dosing strategy. There is only the benefit  of experience, 1 patient at a time.

(Everyone should ask the 3 questions below when prescribed one of these drugs! Jean)


What is a mood stabilizer?

Lately, we are being told that olanzapine is not only an antipsychotic, it is a mood stabilizer. This is not a big surprise for those of us who have used this drug on psychotic bipolar patients and observed that it has positive effects beyond its neuroleptic properties. Whether its mood-stabilizing effects are greater than or equal to its current competition, both antipsychotics and mood stabilizers, remains very much an unanswered question.

Clozapine has been shown recently to have excellent mood-stabilizing properties above and beyond its antipsychotic effect. All of this has precipitated many discussions about the potential of new-generation (atypical) antipsychotics as mood stabilizers.

Santayana once said, "Those that do not learn from history are doomed to repeat it." The current discussions are reminiscent of the first discussions about antimanic agents.

The advent of lithium as the first approved antimanic agent in the 1970s also brought a multitude of studies of many of the then widely used old-generation (typical) antipsychotics as antimanic agents. Most of these studies had positive results. For example, chlorpromazine was shown to be as effective as lithium in the treatment of mania. There was no widespread use of chlorpromazine as an alternative to lithium in mania; however, clinicians were much more excited about lithium, and it quickly became the mainstay of treatment. Occasionally, neuroleptics would be added, particularly in treatment-resistant cases.

Most of the current discussion about mood stabilizers make it sound as if there is a particular magic to them, and often omit the fact that there are a lot of currently available medications with antimanic or mood-stabilizing properties.

The bigger question is the clinical relevance of these meds. Clozapine, for example, may be an excellent mood stabilizer, but
its side-effect profile effectively precludes its use as such in all but the most treatment refractory of cases.

The current challenges for a new mood-stabilizing agent entering the market are:

(1) efficacy: does it work as well as or better than available alternatives?
(2) tolerability: what kind of impact will its side effects have on the patient's life? and
(3) safety: if the patient takes this compound indefinitely, as is usually the case with treatment for bipolar disorder, what might happen?

In my practice, in the early 1990s, I started moving away from lithium and toward valproate as a first-line agent. The reason I did so was because of the answers to the 3 questions above; it was at least as effective if not more so in certain groups of patients; it had a larger therapeutic window and a somewhat milder side-effect profile that made it slightly more tolerable; and it
may be safer on thyroid and renal function in the long term.

Psychopharmacology needs to continue shifting its focus from efficacy to effectiveness, taking into account tolerability, compliance, and safety.

Medications for symptoms or side effects?

One question that must be asked about the use of a particular psychopharmacologic agent is, What is the intent? Is the agent intended to treat a symptom, or a side effect of another agent?

Although we are indeed fortunate in this field to have remarkably effective medications,
they often have side effects that require some sort of intervention, usually in the form of another pill.

Examples of this include benztropine for extrapyramidal symptoms (EPS) of antipsychotics, trazodone or sedative/hypnotics for antidepressant-induced insomnia, modafinil for oversedation of various psychotropics, and perhaps even the recent discussions about adding topiramate to counteract medications that cause weight gain.

Ideally, this addition would do nothing more than increase the effectiveness of the original medication. It is rarely that simple, however, when you add another variable to the equation.

Benztropine is perhaps the worst example of an agent used to treat a side effect. Given routinely to patients on antipsychotics, it can cause confusion, disorganization, and delirium, and it also has some potential for abuse. These side effects of the side-effect medicine often prevent a patient with a psychotic illness from functioning well enough to live or work in the community.

Even worse is that often the same antipsychotic effect can be established with a lower dose of the antipsychotic medication, and the EPS resolves without benztropine at this dose. Thus, we may be medicating side effects with benztropine rather than using the best possible treatment.

Sometimes only 1 medicine works for a particular patient, and sometimes only at 1 dose. When this situation occurs, one needs to be as aggressive as necessary to make sure the medication is as effective as possible, and that means doing whatever is necessary to reduce or eliminate side effects.

If there is no reason to believe that we are stuck with 1 agent or 1 dose, however, we are often not quick enough to change the dose or agent. In particular, we
often assume that the same cocktail of medication needed for acute illness is necessary for maintenance.

One example of this is fluoxetine-induced insomnia, which is often treated with trazodone or a  hypnotic agent at the beginning of treatment, then never discontinued even though the patient may have only needed the extra medication for the first few weeks.

Modafinil is underutilized to treat medication-induced sedation (overly sedated patients are less insistent about dealing with their side effects), but in most cases this medication would only need to be used for a relatively limited time.

Patients acclimate to their medicine, and
the alert, involved clinician will often reduce dose for maintenance.

The larger issue here is the difference between efficacy (ie, how well the medicine works) and effectiveness (ie, whether it is also safe and tolerable enough to actually make the patient better).

With all of the psychotropic agents currently available to us, and many more awaiting approval in the wings, we no longer need to settle for medications with good efficacy, but we can hold out for effectiveness. Sometimes this requires adding another medication, sometimes switching medications, and sometimes adjusting the dose.

A medication with good efficacy but horrible side effects is less effective than one with the same efficacy but a significantly more benign side-effect profile. Fewer and milder side effects can promote increased compliance, and lessen the likelihood of a medical reason to stop the medication (eg, blood dyscrasias, weight gain).

It can also offer greater long-term safety of use and as such increase the agent's effectiveness, or increase the likelihood that it will actually work, and do so for as long as is necessary.

For too long we have paid little attention to side effects and effectiveness because we have had so few choices.

Source
Medscape Psychopharmacology Today
Dosing, Target Symptoms, and Mood Stabilizers
Thomas AM Kramer, MD
[Medscape Mental Health 5(2), 2000.